Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	149.75	135.55	66.33	77.62	76.19	31.27
Short-Term Investments	261.01	232.67	365.34	145.92	364.51	244.69
Cash & Cash Equivalents	410.76	368.22	431.67	223.54	440.7	275.96
Cash Growth	-11.68%	-14.70%	93.11%	-49.28%	59.69%	33.47%
Receivables	61.52	41.12	31.06	27.63	26.2	19.93
Inventory	15.04	15.97	17.03	17.95	21.16	17.41
Other Current Assets	16.05	33.32	19.49	-2.65	-9.55	-5.94
Total Current Assets	503.37	458.64	499.25	266.46	478.5	307.36
Property, Plant & Equipment	0.19	0.32	1.78	1.52	4.18	4.5
Long-Term Investments	40.28	57.18	4.95	112.28	36.2	39.35
Other Long-Term Assets	112.1	105.39	77.45	43.5	52.85	61.11
Total Long-Term Assets	152.57	162.88	84.18	157.29	93.23	104.95
Total Assets	655.94	621.52	583.43	423.76	571.73	412.31
Accounts Payable	12.56	17.4	11.98	6.91	10.55	7.54
Current Debt	0.08	0.15	1.14	0.53	2.05	1.56
Other Current Liabilities	84.57	86.96	59.37	40.11	34.89	29.75
Total Current Liabilities	97.2	104.51	72.49	47.54	47.49	38.84
Long-Term Debt	0	0	0	0	0.5	1.9
Other Long-Term Liabilities	10.87	10.31	9.1	0.41	0.4	0.39
Total Long-Term Liabilities	10.87	10.31	9.1	0.41	0.9	2.29
Total Liabilities	108.07	114.81	81.59	47.95	48.39	41.13
Total Debt	0.08	0.15	1.14	0.53	2.55	3.46
Debt Growth	-86.78%	-86.79%	117.30%	-79.38%	-26.29%	-
Retained Earnings	430.29	402.53	296.39	194.97	82.46	-23.56
Comprehensive Income	0.26	0.61	-0.87	-0.23	0.42	0.26
Shareholders' Equity	547.86	506.71	501.84	375.81	523.34	371.18
Net Cash / Debt	410.69	368.07	430.53	223.01	438.15	272.5
Net Cash / Debt Growth	-11.58%	-14.51%	93.05%	-49.10%	60.79%	31.80%
Net Cash Per Share	3.74	3.29	3.71	1.77	3.53	2.22
Working Capital	406.17	354.13	426.76	218.92	431.01	268.52
Book Value Per Share	5.33	4.89	4.70	3.25	4.54	3.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).